medigraphic.com
Patología Revista Latinoamericana

2011, Number 1

Next >>

Patol Rev Latinoam 2011; 49 (1)

Synovial sarcoma. clinicopathologic and immunohistochemical study of 21 cases with emphasis on TLE-1, p16 and cyclin D-1

Mandujano ÁGJ, Ortiz HC

Language: Spanish
References: 34
Page: 1-10
PDF size: 576.61 Kb.


ABSTRACT

Background: Synovial sarcoma is a malignant neoplasm with specific clinical, morphological and genetic characteristics.
Objective: To report the clinicopathological and immunohistochemical analysis of 21 cases of synovial sarcoma, specially the expression of three markers by immunohistochemistry: TLE-1, cyclin and p16.
Material and method: A clinicopathologic and immnohistochemical study was done of 21 cases of synovial sarcomas (three biphasic, 16 monophasic fibrous and two poorly differentiated) using, among other markers, TLE-1, p16 and cyclin D1.
Results: TLE-1 antibody showed a positive nuclear stain in 62% (13/21) of the cases. p16 antibody revealed a diffuse positive nuclear staining in 14% (3/21), heterogeneous expression in 48% (10/21) and negative staining in 38% (8/21). Cyclin D1 showed increased expression in 71% (15/21), low expression in 19% (4/21), and negative staining in 10% (2/21).
Conclusions: TLE-1 is a useful adjunct immunohistochemical marker in combination with the classic (EMA, keratin and Bcl-2) markers of synovial sarcoma. The expression of p16 and cyclin D1 have been correlated with the previously described genetic alteration of the cell cycle deregulations in synovial sarcoma.


REFERENCES

  1. Fisher C, de Bruijn DRH, Geurts van Kessel A. Synovial sarcoma. IN: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002:200-204.

  2. van de Rijn M, Rubin BP. Gene expression studies on soft tissue tumors. Am J Pathol 2002;16:1531-1534.

  3. Weiss SW, Goldblum JR. Malignant soft tissue tumor of uncertain type. In: Enzinger and Weiss’s Soft Tissue Tumors. 5th ed. Mosby: Philadelphia; 2008:1161-1182.

  4. Khademi B, Daneshbod Y, Negahban S, Daneshbod K, et al. Biphasic parapharyngeal synovial sarcoma: a cytologic and immunocytologic report of a case. Cytojournal 2006;14:1-7.

  5. Vera J, García MD, Marigil M, Abascal M, et al. Biphasic synovial sarcoma of the abdominal wall. Virchows Arch 2006;449:367-372.

  6. Tsukioka T, Inoue K, Iwata T, Mizuguchi S, et al. Resected case of synovial sarcoma in the pleural cavity. Jpn J Thorac Cardiovasc Surg 2006;54:263-266.

  7. Hazelbag HM, Szuhai K, Tanke HJ, Rosenberg C, Hogendoorn PC. Primary synovial sarcoma of the heart: a cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH of a case with a complex karyotype. Mod Pathol 2004;17:1434-1439.

  8. Paláu LMA, Thu-Pham T, Barnard N, Merino MJ. Primary synovial sarcoma of the kidney with rhabdoid features. Int J Surg Pathol 2007;15:421-428.

  9. van de Rijn, Matthijs, Barr FG, Xiong Q, et al. Poorly differentiated synovial sarcoma: an analysis of clinical, pathologic, and molecular genetic features. Am J Surg Pathol 1999;23:106-112.

  10. Suster S, Fisher C, Moran CA. Expression of bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces, and gastrointestinal tract. Am J Surg Pathol 1998;22:863-872.

  11. Terry J, Saito T, Subramanian S, Ruttan C, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 2007;31:240-246.

  12. Baird K, Davis S, Antonescu CR, Harper UL, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005;65:9226-9235.

  13. Allander SV, Illei PB, Chen Y, Antonescu CR, et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002;161:1587-1595.

  14. Subramaniam MM, Noguera R, Piqueras M, Navarro S, et al. p16INK4A (CDKN2A) Gene deletion is a frequent genetic event in synovial sarcoma. Am J Clin Pathol 2006;126:866-874.

  15. Amary MF, Diss TC, Flanagan AM. Molecular characterization of a novel variant of a SYT-SSX1 fusion transcript in synovial sarcoma. Histopathology 2007;51:559-561.

  16. Coindre JM, Pelmus M, Hostein I, Lussan C, et al. Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer 2003;15: 2700-2707.

  17. Fisher C. Synovial sarcoma. Ann Diagn Pathol 1998;2:401-421.

  18. Smith TA, Machen SK, Fisher C, Goldblum JR. Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. Am J Clin Pathol 1999;112: 641-648.

  19. Olsen SH, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing’s sarcoma. Mod Pathol 2006;19:659-668.

  20. Fisher C, Montgomery E, Healy V. Calponin and h-caldesmon expression in synovial sarcoma; the use of calponin in diagnosis. Histopathology 2003;42:588-593.

  21. Nagayama S, Katagiri T, Tsunoda T, Hosaka T, et al. Genomewide analysis of gene expression in synovial sarcoma using a cDNA microarrays. Cancer Res 2002;62:5859-5866.

  22. Segal NH, Pavlidis P, Antonescu CR, Maki RG, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol 2003;163: 691-700.

  23. Ito T, Ouchida M, Morimoto Y, Yoshida A, et al. Significant growth suppression of synovial sarcoma by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 2005;224:311-319.

  24. Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol 2009;22:872-878.

  25. Subramaniam MM, Navarro S, Pellin A, López Guerrero JA, et al. Tissue microarrays profiling of primary and xenotransplanted synovial sarcoma demonstrates the immunophenotypic similarities existing between SYT-SSX fusion gene confirmed, biphasic, and monophasic fibrous variants. Virchows Arch 2006;449:435-447.

  26. Kawai A, Woodruff J, Healey JH, Brennan MF, et al. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Eng J Med 1998;338:153-160.

  27. Inagaki H, Nagasaka T, Otsuka T, Sugiura E, et al. Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol 2000;13:482-488.

  28. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002;62:135-140.

  29. Xie Y, Skytting B, Nilsson G, Gasbarri A, et al. SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: A gain of function of the t(X;18)(p11.2;q11.2) translocation. Cancer Res 2002;62:3861-3867.

  30. Yoo J, Park SY, Kang SJ, Shim SI, Kim BK. Altered expression of G1 regulatory proteins in human soft tissue sarcomas. Arch Path Lab Med 2002;126:567-573.

  31. Antonescu CR, Leung DH, Dudas M, Ladanyi M, et al. Alterations of cell cycle regulators in localized synovial sarcoma. A multifactorial study with prognostic implications. Am J Pathol 2000;156:977-983.

  32. Horvai AE, Kramer MJ, O’Donell R. β-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma. A tissue microarray study. Arch Pathol Lab Med 2006;130:792-798.




2020     |     www.medigraphic.com